BRPI0818302A2 - - Google Patents

Info

Publication number
BRPI0818302A2
BRPI0818302A2 BRPI0818302A BRPI0818302A2 BR PI0818302 A2 BRPI0818302 A2 BR PI0818302A2 BR PI0818302 A BRPI0818302 A BR PI0818302A BR PI0818302 A2 BRPI0818302 A2 BR PI0818302A2
Authority
BR
Brazil
Prior art keywords
mbp
composition
relates
treat
disease
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed filed Critical
Publication of BRPI0818302A2 publication Critical patent/BRPI0818302A2/pt
Publication of BRPI0818302B1 publication Critical patent/BRPI0818302B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
BRPI0818302-3A 2007-10-31 2008-10-30 Composição BRPI0818302B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0721430.7 2007-10-31
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
GB0800962.3 2008-01-18
PCT/GB2008/003673 WO2009056833A2 (en) 2007-10-31 2008-10-30 Composition

Publications (2)

Publication Number Publication Date
BRPI0818302A2 true BRPI0818302A2 (enExample) 2018-08-21
BRPI0818302B1 BRPI0818302B1 (pt) 2022-04-12

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818302-3A BRPI0818302B1 (pt) 2007-10-31 2008-10-30 Composição

Country Status (23)

Country Link
US (3) US8623827B2 (enExample)
EP (1) EP2211892B1 (enExample)
JP (1) JP5361895B2 (enExample)
KR (1) KR101570383B1 (enExample)
CN (1) CN101848725B (enExample)
AT (1) ATE518546T1 (enExample)
AU (1) AU2008320657B2 (enExample)
BR (1) BRPI0818302B1 (enExample)
CA (1) CA2703170C (enExample)
CY (1) CY1112620T1 (enExample)
DK (1) DK2211892T3 (enExample)
EA (1) EA017999B1 (enExample)
EC (1) ECSP10010211A (enExample)
HR (1) HRP20110724T1 (enExample)
IL (1) IL204662A (enExample)
MX (1) MX2010004698A (enExample)
MY (1) MY158800A (enExample)
NZ (1) NZ583924A (enExample)
PL (1) PL2211892T3 (enExample)
PT (1) PT2211892E (enExample)
SI (1) SI2211892T1 (enExample)
WO (1) WO2009056833A2 (enExample)
ZA (1) ZA201001748B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143234D1 (de) 2000-08-21 2010-11-18 Apitope Technology Bristol Ltd Peptid
MX2010004698A (es) 2007-10-31 2010-05-13 Apitope Technology Bristol Ltd Composicion.
AU2009354040A1 (en) 2009-10-12 2012-05-31 Lifebio Laboratories Llc Composition for treatment of Multiple Sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
ES2996275T3 (en) * 2017-01-04 2025-02-12 Worg Pharmaceuticals Zhejiang Co Ltd Therapeutic method using dose escalation protocol for tolerogenic peptides
US20210093695A1 (en) * 2017-08-14 2021-04-01 Apitope Technology (Bristol) Limited Method
KR20230171998A (ko) 2021-04-16 2023-12-21 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 면역학적 관용의 유지를 추적하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
DE60143234D1 (de) * 2000-08-21 2010-11-18 Apitope Technology Bristol Ltd Peptid
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
MX2010004698A (es) 2007-10-31 2010-05-13 Apitope Technology Bristol Ltd Composicion.

Also Published As

Publication number Publication date
CA2703170A1 (en) 2009-05-07
AU2008320657A1 (en) 2009-05-07
KR101570383B1 (ko) 2015-11-19
KR20100036391A (ko) 2010-04-07
CN101848725B (zh) 2013-05-22
MY158800A (en) 2016-11-15
HRP20110724T1 (hr) 2011-12-31
US8623827B2 (en) 2014-01-07
CN101848725A (zh) 2010-09-29
US20140161832A1 (en) 2014-06-12
JP2011500776A (ja) 2011-01-06
US9381234B2 (en) 2016-07-05
ECSP10010211A (es) 2010-08-31
WO2009056833A3 (en) 2009-11-26
ATE518546T1 (de) 2011-08-15
US9775880B2 (en) 2017-10-03
SI2211892T1 (sl) 2011-12-30
CY1112620T1 (el) 2016-02-10
EA201070541A1 (ru) 2010-12-30
EP2211892B1 (en) 2011-08-03
PT2211892E (pt) 2011-10-18
US20100286054A1 (en) 2010-11-11
NZ583924A (en) 2012-06-29
PL2211892T3 (pl) 2012-01-31
EP2211892A2 (en) 2010-08-04
WO2009056833A2 (en) 2009-05-07
CA2703170C (en) 2016-10-11
HK1142803A1 (en) 2010-12-17
BRPI0818302B1 (pt) 2022-04-12
AU2008320657B2 (en) 2013-09-05
ZA201001748B (en) 2011-06-29
JP5361895B2 (ja) 2013-12-04
EA017999B1 (ru) 2013-04-30
IL204662A (en) 2013-07-31
IL204662A0 (en) 2010-11-30
MX2010004698A (es) 2010-05-13
US20160263188A1 (en) 2016-09-15
DK2211892T3 (da) 2011-10-31

Similar Documents

Publication Publication Date Title
IL204662A0 (en) Composition
EA201171220A1 (ru) Мутанты fgf21 и их применение
MX355877B (es) Peptidos terapeuticos.
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA201001322A1 (ru) Вакцины против хламидиоза
MX2015011199A (es) Agentes terapéuticos de csf1.
TN2011000161A1 (en) Fgf21 mutants and uses thereof
EP4491226A3 (en) Optimized fc variants
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
IN2012DN02589A (enExample)
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
WO2010064012A3 (en) Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 )
WO2007101698A3 (en) Modified molecules which promote hematopoiesis
WO2010014830A3 (en) Peptide therapeutics that bind vegf and methods of use thereof
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2008005470A3 (en) Polypeptides that bind membrane proteins
WO2010046461A3 (en) Treatment of intracellular bacterial infections
WO2007044989A3 (en) Modulators of nod1 signaling
UA107458C2 (uk) Мутанти fgf21 та їх застосування
UA102395C2 (en) Fgf21 mutants and use thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/10/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD. (CN)